Gilead Sciences
For more than 35 years, we've been tackling some of the world’s greatest public health challenges. We've revolutionized HIV treatment and prevention, delivered a cure for hepatitis C and made advancements in therapies for viral diseases and certain cancers.
Gilead Sciences: Company
Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information.
Careers at Gilead Sciences
Grow Your Career at Gilead. With more than 18,000 employees spanning across 40+ countries on six continents, we have a global workforce dedicated to creating a better, healthier world for everyone. Explore Opportunities.
Virology, Inflammation, & Oncology Pipeline | Gilead - Gilead …
Nov 6, 2024 · Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, & inflammation. Learn about our pipeline.
Gilead Sciences, Inc. - Investor Relations
At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in.
Medicines - Gilead Sciences
Access the list of approved Gilead therapies across virology including HIV, liver disease including hepatitis and primary biliary cholangitis, oncology & inflammation.
Gilead Sciences, Inc. - Sunlenca® (lenacapavir) Receives FDA …
Dec 22, 2022 · Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV. December 22, 2022. – Sunlenca is the First and Only Approved Capsid Inhibitor-Based HIV Treatment Option –. – New Drug Application Approval Based on High Rates of Sustained Virologic ...
Gilead Sciences, Inc. - Gilead Sciences Announces Fourth Quarter …
Feb 2, 2023 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2022. “2022 marked Gilead’s strongest full year growth in our base business since HCV sales peaked in 2015.
Newsroom | Gilead - Gilead Sciences
Company Statements. This is our global website, intended for visitors seeking information on Gilead’s worldwide business. Some content on this site is not intended for people outside the United States. Visit our Global Operations page for links to our international corporate websites.
Gilead Sciences, Inc. - FDA Approves Veklury® (Remdesivir) for …
Jul 14, 2023 · FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis. July 14, 2023. -- Veklury is Now the First Approved Antiviral Treatment for Patients Across all Stages of Renal Disease --.